Zydus Lifesciences gets EIR from USFDA for Jarod facility
The inspection was a Pre-Approval cum cGMP inspection and it covered 15 ANDAs.;
Advertisement
Ahmedabad: Zydus Lifesciences Ltd. (formerly known as Cadila Healthcare Ltd.), a global lifesciences company has announced that the company has received an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its Jarod injectables manufacturing facility near Vadodara, India. Establishment Inspection Report means the closure of inspection.
The USFDA had inspected the facility from 24th February to 10th March, 2022.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.